[
    [
        {
            "time": "",
            "original_text": "继投下4个“恒瑞”，大半个“上海医药”后，高瓴又来钱了！1160亿又会买谁？大药企、CRO、投资机构争夺战要开始了？",
            "features": {
                "keywords": [
                    "高瓴",
                    "恒瑞",
                    "上海医药",
                    "1160亿",
                    "大药企",
                    "CRO",
                    "投资机构"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技",
                    "投资"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "继投下4个“恒瑞”，大半个“上海医药”后，高瓴又来钱了！1160亿又会买谁？大药企、CRO、投资机构争夺战要开始了？",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]